Severe intracranial vessel tortuosity or stenosis; judicious patient selection is
Stryker Neurovascular Synchro-14 (e.g., Model UPN M00313010) or
A decrease in effectiveness
Stryker Neurovascular Synchro
contraindications, warnings and instructions
in the following patient types:
carotid artery from the petrous segment to the terminus
of age and older) with unruptured large or giant saccular
The Surpass Streamline Flow Diverter is indicated for
Surpass Streamline Flow Diverter
• Retinal ischemia
• Retinal infarction
• Vision impairment

Warnings
This device should only be used by physicians who have received appropriate training in interventional neuroradiology or interventional radiology and preclinical training on the use of this device as established by Stryker Neurovascular.
Do not use if the package is opened or damaged.
Persons allergic to nickel, cobalt chromium or platinum tungsten metal may suffer an allergic response to this Flow Diverter implant.
The system is designed to be manipulated while under high-quality fluoroscopic observation. If resistance is met during manipulation, determine the cause of resistance before proceeding.
Do not torque or rotate the system.
Purge the entire Delivery System carefully to avoid the accidental introduction of air into the system.
If any defects are observed with the Surpass Streamline Flow Diverter, replace the device.
If excessive resistance is encountered during the use of the Surpass Flow Diverter at any time during the procedure, discontinue use of the system. Movement of the system against resistance may result in damage to the vessel, a system component, or the patient.
Repositioning of the Surpass Flow Diverter device in the parent vessel without fully retrieving the device is not advised since it could cause vessel damage and/or perforation. After full deployment, do not re-position.
It is important for the Surpass Streamline Flow Diverter device to be used with the Stryker Neurovascular AXS Catalyst 5 Distal Access Catheter (Model UPN M00313010) or one of the following compatible guidewires:
– Stryker Neurovascular Synchro² (e.g., Model UPN M00326410) or
– Stryker Neurovascular Synchro-14 (e.g., Model UPN M00313010) or
– Boston Scientific Transend EX (e.g., Model UPN M00149050).

(Clinical Warning) Do not use device for ruptured intracranial aneurysms.
(Clinical Warning) A decrease in effectiveness has been observed in subjects aged > 65 years old, subjects with history of smoking and history of prior non-target intracranial aneurysm treated.
(Clinical Warning) Judicious patient selection is important. Patients who fall outside the therapeutic range for antplatelet testing or at the lower limits have an increased risk of developing stent thrombosis, even with additional doses of antplatelet medication. Another effective anti-platelet agent should be considered.
(Clinical Warning) Placement of multiple Surpass Flow Diverter devices may increase the risk of ischemic complications.
(Clinical Warning) Delayed aneurysm rupture may occur with large and giant intracranial aneurysms.

Cautions / Precautions
Experience with device implants indicates that there is a risk of stenosis. Subsequent stenosis may require dilatation of the vessel segment containing the device. The risks and long-term outcome following dilatation of endothelialized devices is unknown at present.
Confirm the device labeling reflects the desired size of the target vessel where the device is to be used.
Do not expose the system to organic solvents (e.g., alcohol).
Appropriate anti-platelet and anti-coagulation therapy should be employed in accordance with standard medical practice.
A thrombosing aneurysm may aggravate pre-existing or cause new symptoms of mass effect and may require medical therapy.
Use product prior to the “Use By” date.
Do not remove the Surpass Flow Diverter from its Delivery System. The device and Delivery System are indicated to perform as a single system and must not be altered.
Carefully inspect the device packaging and system prior to use. Do not use the Surpass Flow Diverter if any component appears damaged or missing.
Carefully remove the tray lid and grasp the Delivery System by its RJV and hoop to facilitate removal from the tray.
Select a device length that is at least 10 mm longer than the intracranial aneurysm neck to maintain a minimum of 5 mm on either side of intracranial aneurysm neck.
Do not attempt to partially deploy and recapture the Surpass Flow Diverter for more than three times.
Use caution when crossing the deployed device with guidewires or other accessory devices.
Dispose of all used devices in accordance with hospital policy for biohazardous materials.
If do not attempt to move the Surpass Flow Diverter more distally once it has begun apposing to the vessel wall.
Do not apply additional force if significant resistance is experienced while attempting to recapture the flow diverter.
This device has not been evaluated for pediatric use.
The safety and effectiveness of the device has not been established in the treatment of small and medium wide-neck intracranial aneurysms.
Operators should take all necessary precautions to limit X-radiation doses to patients and themselves by using sufficient shielding, reducing fluoroscopy times, and modifying X-ray technical factors where possible.
Lower intracranial aneurysm occlusion rates may be associated with giant intracranial aneurysms (> 25 mm).
Do not deploy Surpass Flow Diverter devices in parallel (side by side).
The Surpass Flow Diverter may create local field inhomogeneity and susceptibility artifacts during magnetic resonance angiography (MRA), which may degrade the diagnostic quality to assess effective intracranial aneurysm treatment.
Contents supplied STERILE using an ethylene oxide (EO) process. Do not use if sterile barrier is damaged. If damage is found, call your Stryker Neurovascular representative.
For single patient use only. Do not reuse, reprocess or resterilize. Reuse, reprocessing or resterilization may compromise the structural integrity of the device and/or lead to device failure which, in turn, may result in patient injury, illness or death. Reuse, reprocessing or resterilization may also create a risk of contamination of the device and/or cause patient infection or cross-infection, including, but not limited to, the transmission of infectious diseases from one patient to another. Contamination of the device may lead to injury, illness or death of the patient.
After use, dispose of product and packaging in accordance with hospital administrative and/or local government policy.

Surpass Streamline Flow Diverter
RX ONLY
See package insert for complete indications, contraindications, warnings and instructions for use.

Intended use / Indications for use
The Surpass Streamline Flow Diverter is indicated for use in the endovascular treatment of patients (18 years of age and older) with unruptured large or giant saccular wide-neck (neck width ≥ 4 mm or dome-to-neck ratio < 2) or fusiform intracranial aneurysms in the internal carotid artery from the petrous segment to the terminus arising from a parent vessel with a diameter ≥ 2.5 mm and ≤ 5.3 mm.

Contraindications
The Surpass Streamline Flow Diverter is contraindicated in the following patient types:
• Patients in whom the parent vessel size does not fall within the indicated range.
• Patients in whom antplatelet and/or anticoagulation therapy (e.g., aspirin and clopidogrel) is contraindicated.
• Patients who have not received dual anti-platelet agents prior to the procedure.
• Patients with an active bacterial infection.
• Patients in whom the angiography demonstrates the anatomy is not appropriate for endovascular treatment due to conditions such as:
  – Severe intracranial vessel tortuosity or stenosis; and/or
  – Intracranial vasospasm not responsive to medical therapy.

Potential Adverse Events
Risks that may be associated with the use of the Surpass Flow Diverter in the intracranial arteries include:
• Allergic reaction
• Adverse reaction to anesthesia, contrast or antplatelet/anticoagulation agents
• Aphasia
• Cardiac arrhythmia
• Cranial neuropathy
• Confusion, coma, change in mental status
• Death
• Device migration, fracture, misplacement
• Dissection or perforation of the parent artery
• Embolism (air, clots, device fragments)
• Groin injury (bleeding, pain, vessel/nerve damage)
• Headache
• Hemiplegia
• Hydrocephalus
• Implant or parent vessel stenosis
• Implant thrombosis/occlusion
• Infection
• Intracerebral bleeding
• Mass effect
• Myocardial infarction
• Neurological deficits
• Perforation or rupture of aneurysm
• Progressive neurologic symptoms related to intracranial aneurysm (IA)
• Pseudoaneurysm formation
• Reaction to radiation exposure (i.e., alopecia, burns ranging in severity from skin reddening to ulcers, cataracts, delayed neoplasia)
• Renal failure
• Retropertioneal hematoma
• Seizure
• Stroke
• Subarachnoid hemorrhage
• Thromboembolism from device
• Thrombosis of parent artery or branch vessel
• Transient ischemic attack (TIA)
• Vasospasm
Risks that are eye related with the use of the Surpass Flow Diverter may include:
• Amaurosis fugax/transient blindness
• Blindness
• Diplopia
• Reduced visual acuity/field
• Retinal artery occlusion